Clinical Trial Detail

NCT ID NCT04323202
Title Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Brian Gastman
Indications

basal cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.